Balanced news tone
News Sentiment
SUPN sentiment intelligence
Supernus Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
46 relevant articles
News tone and price action are not far from neutral.
75/100 classification confidence.
directly relevant articles
high-authority source matches
+0.9% over one week, +9.1% over four weeks, trend inactive, and materially above fair value.
Supernus marks five years since Qelbree ADHD drug approval By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
75/100 classification
One-week reaction
0.9%
Price digesting
Trend fit
Trend inactive
9.1% over four weeks
Fair value
32.1%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
18
Neutral
26
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com South Africa
Direct company coverage
Supernus marks five years since Qelbree ADHD drug approval By Investing.com
Supernus Pharmaceuticals announced the five-year anniversary of its Qelbree ADHD drug's FDA approval. The non-stimulant medication, approved for pediatric patients in 2021 and adults in 2022, has seen over 3 million prescriptions filled and contributed to Supernus's 16% revenue g
- Tone
- Positive 65/100
- Event
- Earnings
- Published
- 14 Jul 2026 16:13
- Source
- Investing.com South Africa
GlobeNewswire
Direct company coverage
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Supernus Pharmaceuticals is celebrating the five-year anniversary of the FDA approval of Qelbree (viloxazine extended-release capsules) for ADHD. Since its initial approval for pediatric ADHD in April 2021 and subsequent approval for adults in April 2022, Qelbree has provided a v
- Tone
- Positive 70/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 12:39
- Source
- GlobeNewswire
GuruFocus
Direct company coverage
SUPN Maintained by Cantor Fitzgerald -- Price Target Raised to $67.00
Cantor Fitzgerald maintained an Overweight rating for Supernus Pharmaceuticals (SUPN) and raised its price target from $63.00 to $67.00, reflecting confidence in the company's growth potential in central nervous system diseases. Despite this positive analyst outlook, GuruFocus in
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 09 Jul 2026 16:47
- Source
- GuruFocus
Market source
Direct company coverage
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Supernus Pharmaceuticals (SUPN) shares climbed 5.2% due to notable trading volume, driven by investor confidence in its growing neuroscience business and strong commercial performance, particularly with drugs like Qelbree and Gocovri. Despite positive revenue growth, the company'
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 09 Jul 2026 13:25
- Source
- Market source
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
This page from TradingView displays the enterprise value to EBITDA forward for Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). It is a financial data point for the pharmaceutical company, accessible under the financials and overview sections on the platform. The content primarily
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 10:42
- Source
- TradingView
BBN Times
Direct company coverage
Jack Khattar: Innovator, Business Leader, and Founder, President and CEO of Supernus Pharmaceuticals
This article profiles Jack Khattar, the founder, president, and CEO of Supernus Pharmaceuticals, highlighting his journey from a Lebanese-born businessman to a leader in the American specialty pharmaceutical industry. It details his educational background, early career at major p
- Tone
- Positive 86/100
- Event
- Market update
- Published
- 07 Jul 2026 18:11
- Source
- BBN Times
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – BX:S49
This article provides the enterprise value to forward EBITDA for Supernus Pharmaceuticals, Inc. (BX:S49). It presents this financial metric for the company, listed on the BX Swiss exchange. The content appears to be a stub or a data point from a financial data provider, indicatin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 15:11
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
This article displays the "Price to sales forward" metric for Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) as part of its financial data provided on the TradingView platform. The content is primarily a listing of navigation and source information related to the financial data fo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 09:11
- Source
- TradingView
Sahm
Direct company coverage
Supernus Pharmaceuticals (SUPN) Following Shelf Filing Has Its Undervalued Case In Focus
Supernus Pharmaceuticals (SUPN) has filed a US$177.52 million shelf registration, potentially signaling a future capital raise. Despite strong recent share price gains and a positive longer-term momentum, the company is trading below the average analyst price target and faces
- Tone
- Positive 65/100
- Event
- Analyst action
- Published
- 06 Jul 2026 09:42
- Source
- Sahm
TradingView
Direct company coverage
Price to sales forward of Supernus Pharmaceuticals, Inc. – FWB:S49
This article provides financial information for Supernus Pharmaceuticals, Inc. (S49) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-sales ratio. It appears to be a stub or data-oriented page from TradingView, lacking detailed analysis but presentin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 20:39
- Source
- TradingView
Stock Traders Daily
Direct company coverage
Discipline and Rules-Based Execution in SUPN Response - Stock Traders Daily
This article provides a detailed analysis of Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), highlighting strong near-term sentiment that could lead to a long-term positive bias. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 04:10
- Source
- Stock Traders Daily
TradingView
Direct company coverage
Price to book forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
This article provides a financial overview of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), focusing on its forward price-to-book ratio. It presents current market data and notes that the market was closed at the time of publication, indicating no active trades. The content is p
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 20:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
This article displays the Enterprise Value to EBIT forward for Supernus Pharmaceuticals, Inc. (LSE:0LB2) on TradingView. It appears to be a stub or data point rather than a textual analysis, showing the financial metric, period, value, and changes. The page structure includes typ
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 05:10
- Source
- TradingView
TradingView
Direct company coverage
Supernus Pharmaceuticals, Inc. Actuals & Estimates (BX:S49)
This article provides an overview of Supernus Pharmaceuticals, Inc. (BX:S49), covering its financial actuals and estimates. It includes analyst price targets, past earnings performance (with a significant positive surprise), revenue figures, and upcoming earnings dates. The artic
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 26 Jun 2026 18:10
- Source
- TradingView
TradingView
Direct company coverage
SUPN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Supernus Pharmaceuticals, Inc. (SUPN) stock, including current price, historical performance, analyst price targets, and key financial metrics. It highlights that analysts estimate a max price of $66.00 and a min price of $55.00, and also cove
- Tone
- Positive 60/100
- Event
- Analyst action
- Published
- 26 Jun 2026 17:39
- Source
- TradingView
TradingView
Direct company coverage
S49 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Supernus Pharmaceuticals, Inc. (S49) stock, outlining analysts' price targets, past earnings performance, and future revenue and earnings estimates. It also details financial metrics such as EBITDA, employee count, and confirms that the compan
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 16:40
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
This page provides financial data on Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), specifically focusing on its price-to-earnings forward ratio. The content indicates that the financial metric changes over various periods.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 08:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
This article provides financial data for Supernus Pharmaceuticals, Inc. (LSE:0LB2), specifically focusing on its Enterprise Value to EBITDA (forward-looking). The content highlights the stock's listing on the London Stock Exchange and is presented within the TradingView platform,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 04:09
- Source
- TradingView
TradingView
Direct company coverage
Supernus Pharmaceuticals, Inc. Actuals & Estimates (LSX:A1JX3U)
This article provides an overview of Supernus Pharmaceuticals, Inc. (A1JX3U) stock, including its current price, analyst forecasts, historical highs and lows, volatility, market capitalization, and financial performance. It highlights that the company's stock is currently trading
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 25 Jun 2026 19:10
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
The article displays the "Price to sales forward" financial metric for Supernus Pharmaceuticals, Inc. (LSE:0LB2) on TradingView. It appears to be a financial data snippet rather than a news article, indicating that no specific value or change could be found within the provided te
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 16:40
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Supernus Pharmaceuticals, Inc. – LSE:0LB2
This article focuses on the "Price to earnings forward" metric for Supernus Pharmaceuticals, Inc. (LSE:0LB2) as listed on TradingView. It appears to be a stub or a data point within a larger financial platform, indicating that specific value and change data for this metric would
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 09:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Supernus Pharmaceuticals, Inc. – NASDAQ:SUPN
The article provides the enterprise value to revenue forward for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and appears to be a financial data point from TradingView. It displays basic company information, stock market data, and navigation for various financial tools and educat
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 07:41
- Source
- TradingView
GuruFocus
Direct company coverage
Q4 2025 Supernus Pharmaceuticals Inc Earnings Call Transcript
Supernus Pharmaceuticals Inc. reported record total revenues of $719 million in 2025, a 27% increase year-over-year, driven by strong growth in its four key products. Despite this revenue growth and strategic acquisitions like Sage Therapeutics, the company recorded a GAAP net lo
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 08:39
- Source
- GuruFocus
富途牛牛
Direct company coverage
Supernus Pharmaceuticals Insiders Sold US$2.1m Of Shares Suggesting Hesitancy
This article analyzes recent insider selling at Supernus Pharmaceuticals, noting that insiders sold US$2.1 million worth of shares over the past year. While some insider selling is normal, the volume at Supernus indicates potential hesitancy among those with intimate knowledge of
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 24 Jun 2026 03:40
- Source
- 富途牛牛
TradingView
Direct company coverage
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
This article analyzes the Q1 performance of several branded pharmaceutical companies, focusing on Supernus Pharmaceuticals (SUPN) and comparing it to peers like Eli Lilly (LLY), Zoetis (ZTS), Corcept (CORT), and Phibro Animal Health (PAHC). It highlights sector trends including a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 03:09
- Source
- TradingView
Simply Wall Street
Direct company coverage
Supernus Pharmaceuticals (SUPN) Stock Could Be 29.4% Undervalued After Strong Quarterly Results
Supernus Pharmaceuticals (SUPN) recently reported strong quarterly results with significant revenue and net profit growth, suggesting the stock may be undervalued by 29.4% according to analyst narratives, with a fair value near $62.83. Despite recent share price fluctuations, the
- Tone
- Positive 76/100
- Event
- Earnings
- Published
- 23 Jun 2026 01:40
- Source
- Simply Wall Street
Sahm
Direct company coverage
How Strong Quarterly Results and MERGE Partnership Will Impact Supernus Pharmaceuticals (SUPN) Investors
Supernus Pharmaceuticals recently posted strong quarterly revenue and net profit growth and expanded its partnership with MERGE for digital marketing. This combination of improved financial performance and an enhanced omnichannel marketing strategy for products like Qelbree and i
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 21 Jun 2026 02:40
- Source
- Sahm
Investing.com
Direct company coverage
Supernus Pharmaceuticals shareholders approve director elections and key proposals
Supernus Pharmaceuticals shareholders approved the election of two Class I directors, the compensation for named executive officers, and the appointment of KPMG LLP as their independent public accounting firm. Additionally, shareholders voted to amend the 2021 Equity Incentive Pl
- Tone
- Positive 60/100
- Event
- Market update
- Published
- 19 Jun 2026 01:39
- Source
- Investing.com
Stock Titan
Direct company coverage
Supernus (NASDAQ: SUPN) holders approve directors, say-on-pay and equity plan
Supernus Pharmaceuticals, Inc. announced that stockholders approved all four proposals at its 2026 annual meeting. This includes the election of Class I directors Frederick M. Hudson and Charles W. Newhall, III, the non-binding approval of executive compensation, ratification of
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 19 Jun 2026 01:09
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Supernus Expands Partnership With MERGE as AI-Powered Agency of Record
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 17 Jun 2026 14:15
- Source
- GlobeNewswire